Merck & Co., Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $15.04bn | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $29.52bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $4.02bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $7.95bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $13.32bn | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $17.60bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $2.70bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $5.18bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $277.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $519.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $637.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $1.46bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$5.97bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$3.15bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$2.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$1.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$2.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$1.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 2,539,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 2,539,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $5.04bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months2023-01-01 to 2023-06-30 | $3.74bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2023-01-01 to 2023-06-30 | $487.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-06-30 | $5.66bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $29.98bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $104.47bn | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $23.39bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-06-30 | $34.07bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-06-30 | $2.84bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-06-30 | $38.69bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-027770. Last ingested by Listed: Oct 29, 2026, 06:44 ET. Listed shows no prices and gives no investment advice.